| AASLD

Model for end‐stage liver disease exception points for treatment‐responsive hepatocellular carcinoma

Read more about Model for end‐stage liver disease exception points for treatment‐responsive hepatocellular carcinoma

Neehar D. Parikh, Amit G. Singal – 27 May 2016

Epidemiology of nonalcoholic fatty liver disease: A primer

Read more about Epidemiology of nonalcoholic fatty liver disease: A primer

Albert Do, Joseph K. Lim – 27 May 2016

Cardiopulmonary examination

Read more about Cardiopulmonary examination

Michael J. Krowka – 27 May 2016

Impact of grazoprevir and elbasvir in the treatment of hepatitis C virus–infected patients with chronic kidney disease and end‐stage renal disease

Read more about Impact of grazoprevir and elbasvir in the treatment of hepatitis C virus–infected patients with chronic kidney disease and end‐stage renal disease

Fernando Pedraza, Marco Ladino, David Roth – 27 May 2016

Circulating let‐7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C

Read more about Circulating let‐7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C

Kentaro Matsuura, Valeria De Giorgi, Cathy Schechterly, Richard Y. Wang, Patrizia Farci, Yasuhito Tanaka, Harvey J. Alter – 26 May 2016 – The goal of this study was to determine whether an association exists between circulating microRNA (miRNA) levels and disease progression in chronic hepatitis C (CHC), whether plasma or extracellular vesicles (EVs) were optimal for miRNA measurement and their correlation with hepatic miRNA expression, and the mechanistic plausibility of this association. We studied 130 CHC patients prospectively followed over several decades.